Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes

Exclusion Criteria

• •History of pancreatitis or current ongoing symptomatic biliary disease or pancreatitis
• •History of significant gastrointestinal surgery,
• •History of significant cardiovascular disease
• •History of a seizure disorder
• •Documented hypertension or hypotension
• •Use of oral antidiabetic agents, except for metformin, within 14 days before investigational product administration.
• •Current hepatic disease or abnormal liver function tests
• •Positive test result for hepatitis B, hepatitis C, or human immunodeficiency virus infection 1 or 2
• •History of regular alcohol consumption (exceeding 7 drinks/week for women or 14 drinks/week for men)
• •Female subject is pregnant (confirmed by laboratory testing), lactating, or less than 6 weeks postpartum
• •Known allergy to any GLP-1 analog or excipients of albiglutide, Baker's yeast, or insulin
• •History of type 1 diabetes,
• •Prior exposure to GLP-1 agents, including albiglutide
• •Blood donation over 500 mL within 8 weeks before Screening